IE stock · Healthcare sector · Medical Devices
Company Logo

Medtronic plc

MDTNYSE

102.53

USD
-0.22
(-0.21%)
Market Closed
28.25P/E
18Forward P/E
1.09P/E to S&P500
137.548BMarket CAP
2.40%Div Yield
Upcoming Earnings
26 May
Shares Short
4/29/22
9.88M
Short % of Float
0.74%
Short % of Shares Outs.
0.74%
% Held by Insiders
0.24%
% Held by Institutions
83.24%
Beta
0.75
PEG Ratio
1.49
52w. high/low
135.89/98.38
Avg. Daily Volume
5.80M
Return %
Stock
S&P 500
1 year
(19.82)
(6.46)
3 years
16.25
36.32
5 years
23.72
63.92
Scale: |
High
Low
57.99
44.87
56.97
28.33
44.94
24.06
46.66
30.80
43.33
30.18
44.79
35.67
58.85
41.16
75.66
53.33
79.50
55.54
89.27
71.03
89.72
69.35
100.15
76.41
115.94
81.66
122.15
72.13
135.89
98.38
114.31
98.79
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
9.37
10.70
11.95
13.06
14.30
14.79
15.36
16.28
16.97
18.49
20.45
21.55
22.08
22.70
21.57
22.39
23.63
Earnings per share
2.11
2.44
1.97
1.94
2.80
2.87
3.43
3.40
3.06
2.44
2.51
2.92
2.29
3.44
3.57
2.68
3.65
FCF per share
0.80
1.99
2.55
2.88
3.16
2.96
3.77
4.34
4.55
3.95
2.96
4.08
2.67
4.36
4.49
3.63
4.22
Dividends per share
0.39
0.44
0.50
0.75
0.82
0.90
0.97
1.04
1.11
1.22
1.52
1.72
1.84
2.00
2.16
2.32
2.47
CAPEX per share
1.03
0.60
0.54
0.59
0.57
0.51
0.47
0.45
0.40
0.52
0.74
0.91
0.79
0.84
0.90
1.01
1.01
Book Value per sh.
7.79
9.55
10.20
11.50
13.22
14.82
16.24
18.32
19.40
48.59
36.93
36.47
37.38
37.20
37.84
38.24
38.55
Comm.Shares outs.
1,205
1,150
1,131
1,118
1,106
1,077
1,054
1,019
1,002
1,096
1,410
1,379
1,357
1,346
1,341
1,345
1,345
Avg. annual P/E ratio
24.0
21.2
23.7
18.0
13.9
12.9
11.6
15.1
20.6
30.4
31.9
27.8
38.4
28.7
28.6
45.3
28.3
P/E to S&P500
1.3
1.2
1.1
0.3
0.7
0.8
0.8
0.9
1.1
1.5
1.4
1.2
1.5
1.2
0.8
1.5
1.1
Avg. annual div. yield
0.8%
0.8%
1.1%
2.2%
2.1%
2.4%
2.4%
2.0%
1.8%
1.6%
1.9%
2.1%
2.1%
2.0%
2.1%
1.9%
2.2%
Revenue (m)
11,292
12,299
13,515
14,599
15,817
15,933
16,184
16,590
17,005
20,261
28,833
29,710
29,953
30,557
28,913
30,117
31,785
Operating margin
32.8%
30.4%
30.2%
28.6%
27.1%
28.4%
29.9%
28.8%
28.3%
18.6%
18.4%
17.9%
22.2%
20.5%
16.6%
14.9%
17.9%
Depreciation (m)
544
583
637
699
772
804
833
819
850
1,306
2,820
2,917
2,644
2,659
2,663
2,702
2,703
Net profit (m)
2,547
2,802
2,231
2,169
3,099
3,096
3,617
3,467
3,065
2,675
3,538
4,028
3,104
4,631
4,789
3,606
4,914
Income tax rate
19.4%
20.3%
22.7%
16.4%
21.9%
16.8%
17.6%
18.4%
17.3%
23.3%
18.4%
12.6%
45.5%
10.5%
(17.0)%
6.8%
9.7%
Net profit margin
22.6%
22.8%
16.5%
14.9%
19.6%
19.4%
22.3%
20.9%
18.0%
13.2%
12.3%
13.6%
10.4%
15.2%
16.6%
12.0%
15.5%
Working capital (m)
5,971
5,355
3,787
4,313
4,718
4,403
3,658
13,902
15,651
21,671
16,435
10,609
12,896
13,495
11,665
14,039
14,376
Long-term debt (m)
5,486
5,578
5,802
6,772
6,944
8,112
7,359
9,408
10,120
33,752
30,109
25,921
23,699
24,486
22,021
26,378
24,290
Equity (m)
9,383
10,977
11,536
12,851
14,629
15,968
17,113
18,671
19,443
53,230
52,063
50,294
50,720
50,091
50,737
51,428
52,542
ROIC
16.7%
16.5%
12.0%
11.5%
14.9%
13.5%
14.2%
12.2%
10.4%
3.3%
5.0%
5.8%
4.6%
7.3%
7.6%
5.3%
6.6%
Return on capital
16.1%
18.0%
13.0%
11.9%
15.6%
13.7%
14.2%
13.3%
10.8%
3.9%
5.7%
5.7%
7.5%
7.4%
5.7%
5.2%
6.6%
Return on equity
27.1%
25.5%
19.3%
16.9%
21.2%
19.4%
21.1%
18.6%
15.8%
5.0%
6.8%
8.0%
6.1%
9.2%
9.4%
7.0%
9.4%
Plowback ratio
81.7%
82.0%
74.7%
61.1%
70.7%
68.7%
71.8%
69.6%
63.6%
50.0%
39.5%
41.0%
19.7%
41.8%
39.6%
13.5%
32.4%
Div.&Repurch./FCF
425.0%
53.0%
59.2%
36.9%
50.7%
63.4%
59.6%
46.0%
51.8%
60.2%
107.3%
97.6%
117.9%
77.9%
59.1%
67.5%
79.8%
Capital Structure
3 Mar · 2022 | Q3
All numbers in millions
Total liabilities
$ 39,091
Total assets
$ 91,804
Long-term debt
$ 24,290
Cash and equiv.
$ 3,479
Goodwill
$ 41,346
Retained earnings
$ 29,607
Common stock
1,344
Enterprise Value
$ 158,359
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
9,848
10,948
10,817
Receivables
6,222
4,645
5,462
Inventory
3,753
4,229
4,313
Other
2,144
1,956
1,156
Current assets
21,967
22,031
22,548
Acc. Payable
1,953
1,996
2,106
Debt due
- -
2,776
11
Other
6,519
5,594
6,392
Current liabilities
8,472
10,366
8,509
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
4.16%
0.40%
7.90%
Cash flow
(18.87)%
2.59%
5.67%
Earnings
(24.70)%
1.24%
2.51%
Dividends
7.81%
7.05%
14.24%
Book value
1.36%
0.56%
20.41%
Insider Trading
Type
Shares
Date
Goldsmith Andrea Jo
InKind
262
05/03/22
Anderson Richard H
InKind
262
05/03/22
Powell Kendall J
InKind
262
05/03/22
Oleary Denise M
InKind
262
05/03/22
Nabel Elizabeth G
InKind
262
05/03/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
7,493
7,706
7,717
5,997
28,913
2021
6,507
7,647
7,775
8,188
30,117
2022
7,987
7,847
7,763
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.64
1.02
1.43
0.48
3.57
2021
0.36
0.37
0.94
1.01
2.68
2022
0.57
0.97
1.10
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.54
0.54
0.54
0.54
2.16
2021
0.58
0.58
0.58
0.58
2.32
2022
0.63
- -
0.63
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Omar Ishrak
Full-time employees:
90,000
City:
DUBLIN
Address:
20 On Hatch, Hatch Street Lower
IPO:
Mar 17, 1980
Website:
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.